Reaching the Empowered Patient -- Opportunities and Challenges in DTC Marketing

Date: February 22, 2010
Pages: 53
Price:
US$ 395.00
Publisher: FirstWord
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: R44F6625CD2EN
Leaflet:

Download PDF Leaflet

Reaching the Empowered Patient -- Opportunities and Challenges in DTC Marketing
Direct marketing restrictions are everywhere. Consumers are suspicious. Physicians are shutting their doors to reps and the market is changing.

Bottom line: Lackluster profits across the industry.

But where one door closes, a window opens.

While the $5 billion Direct to Consumer Advertising (DTCA) still faces considerable hurdles and legislative obstacles everywhere but in the US and New Zealand, DTCA is nevertheless a promising growth area for pharmaceutical marketing.

Legislators in the European Union — who’ve long held a stranglehold on DTCA — are now considering loosening their grip. In doing so, they’ll open a portal through which pharmaceutical companies can market non-promotional information such as safety and dosage. According to the British Medicines and Health Care products Regulatory Agency (MHRA), the resulting boost in patient awareness of disease symptomatology and prevention could save the UK up to £630 million a year.

And although the industry as a whole pulled back from DTC marketing in 2008, there are signs of renewed investment — Pfizer increased spending on Lipitor by 319 per cent in the first half of 2009 — and renewed interest in emerging platforms like social media, direct email and the internet. While there are moves afoot by the Food and Drug Administration to publish draft guidelines governing web-based marketing by the end of 2010, the opportunities afforded by new media still hold great promise. But will it be enough?

Key insights into a changing environment

FirstWord’s insightful overview of the current and future DTCA environment both in the US and Europe offers critical analysis for an industry in flux. Covering key case studies examining how DTCA budgeting can affect the financial performance of drugs, examples of great — and not so great — ads, as well as highlights of the companies leading the way in social media marketing, the report is a concise, astute summary of where DTCA is, and where it’s heading.

The report investigates the current direct to consumer marketing environment to establish:
  • A detailed scan of the current and future regulatory environment in the US and Europe
  • The net benefits of reinvestment in DTCA, especially in emerging communication platforms

The report
  • Offers a snapshot of the current DTCA market in the US and Europe
  • Overviews the successes and failures of the main players, including Pfizer, GSK, Sanofi-aventis, Eli Lilly and Roche
  • Details anticipated regulatory hurdles and critical paths to overcome them
  • Discusses promising DTCA strategies, challenges and options
  • Focuses on opportunities and concerns surrounding emerging communications platforms, such as the internet, social media, web advertising, direct email marketing and YouTube
  • Establishes which drug classes grab the most consumer advertising — and details key DTCA competitors

Key comments

Access to “high-quality, non-promotional information on diseases and treatments” would allow patients to take responsibility for their own health, according to Arthur Higgins, president of the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Pharmaceutical companies need to be transparent while providing information about a drug. A recent study by Jatin Shah, from Duke University, US, established that no fair balance exists on the pharmaceutical brand websites between the information related to drug efficacy and its side effects.

Consumers are increasingly using the internet as a potential source of health related information. Some of the main information people search for online includes the benefits and risks of a medicine, how the medicine works, and its effectiveness compared to other drugs.
EXECUTIVE SUMMARY

IMPORTANCE OF DTC MARKETING

Benefits of DTC Advertising (DTCA) for Pharmaceutical Companies
Benefits of DTCA for Patients

REGULATORY SITUATIONS

FDA Rules on DTC Marketing
The Regulatory Situation in Europe

PHARMACEUTICAL DTCA MARKET

DTCA CHANNELS

TV ADVERTISING

THE INTERNET

Influences Leading Patients to the Drug Sites
Methods of Online Marketing
  Branded Site Marketing
  Unbranded Site Marketing
  Search Engine Marketing (SEM)
  E-mail Marketing
  Social Media Marketing
    Benefits of Social Media Marketing
    Concerns about Social Media
  Patient Assistance Programs and Loyalty Cards

CONTROVERSIAL AND LESS SUCCESSFUL DTC CAMPAIGNS

DTC TRENDS IN THE EUROPEAN MARKET

Roche Xenical
Eli Lilly campaign in the UK
Pfizer Campaign

PFIZER YOUTUBE IN EUROPE

FACTORS INFLUENCING DTC BUDGETING IN A PHARMACEUTICAL COMPANY

The Impact of DTC Budgeting - Case Studies
  GSK’s Advair
  Sanofi-aventis’ Ambien

WHAT CLASS OF DRUGS GETS THE MOST CONSUMER ADVERTISING?

COMPETITORS AND DTCA

HOW TO MEASURE THE EFFECTIVENESS OF DTC ADVERTISING

DTC CHALLENGES

DTCA CONTROVERSIES

EMERGING TRENDS FOR SUCCESSFUL DTC ADVERTISING

FUTURE DTCA MARKET OUTLOOK

INDEX
Skip to top


Ask Your Question

Reaching the Empowered Patient -- Opportunities and Challenges in DTC Marketing
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: